Therefore, TKI-sensitive lung cancer cell lines (PC9, exon 19 deletion; H3255, L858R EGFR mutant) [40] and TKI-resistant lung cancer cell lines (PC9/gef, exon 19 deletion, acquired resistance; H1975, L858R/T790M EGFR mutant) [38] were used to evaluate the anticancer effectiveness of digoxin. Here, EGFR is linked to lung cancer.